We haven’t lowered tariffs on food. We haven’t done many new trade deals, and certainly not one with the United States. Hardly any rules and regulations have been repealed, and if anyone thought it was going to help fix the NHS then the winter crisis will have disappointed them. Six years since we voted to leave, and two years after we finally severed our ties with the European Union, Brexit wins have been noticeable mainly by their absence. But hold on. We may finally have one – a partnership with the drugs developer BioNTech to pioneer cancer treatments.
The German company, best known for developing the Covid vaccine that was jabbed into most of our arms courtesy of its larger partner Pfizer, has announced a partnership with the UK to develop a new range of MRNA based cancer vaccines.
Comments
Join the debate for just $5 for 3 months
Be part of the conversation with other Spectator readers by getting your first three months for $5.
UNLOCK ACCESS Just $5 for 3 monthsAlready a subscriber? Log in